Obagi Medical (OMPI) Guides Q1, FY12
Tweet
Share
E-mailGet Alerts OMPI Hot Sheet
Price: $23.98 --0%
Financial Fact:
Research and development expenses: 493K
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Research and development expenses: 493K
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Obagi Medical Products (Nasdaq: OMPI) sees Q1 EPS of 10-11 cents on sales of $27-$29 million. The Street is currently looking for EPS of 20 cents on sales of $28.05 million.
The company expects FY12 EPS from core operations of 89-91 cents, vs. the consensus estimate of 89 cents.
The company expects FY12 EPS from core operations of 89-91 cents, vs. the consensus estimate of 89 cents.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
- Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
- Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
Create E-mail Alert Related Categories
GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
